Biomarkers for immunotherapy in urological cancers

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Immunotherapies targeting immune checkpoints have advanced treatment for urological malignancies.
• A significant portion of patients do not respond to current immunotherapies.
• Predictive biomarkers are crucial for optimizing treatment selection but remain under investigation.

Purpose of the Study:

• To review the literature and identify biomarkers for predicting immunotherapy response in patients with urological cancers.
• To consolidate current knowledge on biomarkers relevant to immunotherapy in urological malignancies.

Main Methods:

• A comprehensive literature search was conducted on PubMed for publications from 2016 to 2017.
• Relevant abstracts from oncological scientific meetings in 2017 were also included.
• The review focused on biomarkers associated with immunotherapy in urological cancers.

Main Results:

• Immune checkpoint inhibitors have demonstrated significant efficacy in metastatic renal cell carcinoma (RCC) and urothelial cancer.
• The identified literature highlights ongoing research into various biomarkers.
• Clinical trials data from 2016-2017 were analyzed for biomarker relevance.

Conclusions:

• Checkpoint inhibitors offer substantial benefits for metastatic RCC and urothelial cancer.
• There is a critical need for developing predictive biomarkers to personalize immunotherapy selection.
• Identifying patients likely to respond to immunotherapy is essential for improving treatment outcomes.